Unicycive Therapeutics, Inc. (UNCY)

Market Cap	138.88M +164.7%
Revenue (ttm)	n/a
Net Income	-39.89M
EPS	-2.11
Shares Out	27.39M
PE Ratio	n/a
Forward PE	12.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	509,095
Open	5.14
Previous Close	5.05
Day's Range	5.03 - 5.22
52-Week Range	3.71 - 8.74
Beta	1.78
Analysts	Strong Buy
Price Target	38.59 (+661.14%)
Earnings Date	Aug 11, 2026

About UNCY

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 13, 2021
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: UNCY
• Website: https://unicycive.com

Analyst Summary

According to 10 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price target is $38.59, which is an increase of 661.14% from the latest price.

Price Target

$38.59

(661.14% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 10, 2026

Data Sources Report a data error